Sometimes a company just needs to prove it can actually make money. Rockwell Medical Inc. (RMTI) delivered exactly that kind of proof Tuesday, and investors rewarded the medical device maker with a 22% pop in the share price.
The preliminary numbers tell a pretty compelling turnaround story. Fourth-quarter sales came in around $18.6 million, comfortably ahead of the Street's $16.55 million estimate. For the full year, Rockwell Medical expects revenue near $69.5 million—respectable growth for a company that's been fighting to find its footing.
But here's what really matters: the company hit positive adjusted EBITDA and generated actual operating cash flow during the quarter. That operating cash flow totaled roughly $2.3 million, which might not sound like much, but for a company that's been burning cash, it's a meaningful inflection point.
The margin story is equally encouraging. Gross margin jumped to approximately 22% in the fourth quarter, up from just 14% in Q3. That's the kind of sequential improvement that suggests operational progress, not just accounting tricks.
Rockwell Medical also expects to end the year with about $25 million in cash and investments, providing some runway for the turnaround effort.
"Our preliminary financial results for the fourth quarter 2025 reflect our unrelenting drive towards making Rockwell Medical a profitable company and positioning the Company for long-term stability and success," said Mark Strobeck, the company's CEO.
Looking ahead, Strobeck outlined a 2026 strategy focused on sales growth, improved profitability, and product diversification—the usual playbook for a company trying to stabilize and expand.
Despite Tuesday's rally, RMTI shares remain down over 56% over the past year, trading at $1.17. The preliminary results suggest the company might finally be heading in the right direction, but there's clearly a lot of ground to make up.
